[go: up one dir, main page]

ATE267595T1 - Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten - Google Patents

Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten

Info

Publication number
ATE267595T1
ATE267595T1 AT01974413T AT01974413T ATE267595T1 AT E267595 T1 ATE267595 T1 AT E267595T1 AT 01974413 T AT01974413 T AT 01974413T AT 01974413 T AT01974413 T AT 01974413T AT E267595 T1 ATE267595 T1 AT E267595T1
Authority
AT
Austria
Prior art keywords
sibutramines
receptors
compositions
treatment
obesity containing
Prior art date
Application number
AT01974413T
Other languages
English (en)
Inventor
Odile Piot-Grosjean
Philippe Picaut
Francois Petitet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8854974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE267595(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE267595T1 publication Critical patent/ATE267595T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01974413T 2000-10-04 2001-10-01 Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten ATE267595T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012646A FR2814678B1 (fr) 2000-10-04 2000-10-04 Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
PCT/FR2001/003022 WO2002028346A2 (fr) 2000-10-04 2001-10-01 Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite

Publications (1)

Publication Number Publication Date
ATE267595T1 true ATE267595T1 (de) 2004-06-15

Family

ID=8854974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01974413T ATE267595T1 (de) 2000-10-04 2001-10-01 Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten

Country Status (29)

Country Link
EP (1) EP1328269B2 (de)
JP (1) JP4221221B2 (de)
KR (1) KR20030036885A (de)
CN (1) CN100409845C (de)
AT (1) ATE267595T1 (de)
AU (2) AU2001293936B2 (de)
BG (1) BG107739A (de)
BR (1) BR0114410A (de)
CA (1) CA2424934A1 (de)
DE (1) DE60103556T3 (de)
DK (1) DK1328269T5 (de)
EA (1) EA005924B1 (de)
EE (1) EE200300121A (de)
ES (1) ES2217191T5 (de)
FR (1) FR2814678B1 (de)
HR (1) HRP20030249A2 (de)
HU (1) HUP0302044A3 (de)
IL (1) IL155236A0 (de)
MX (1) MXPA03002845A (de)
NO (1) NO20031521L (de)
NZ (1) NZ524904A (de)
PL (1) PL362833A1 (de)
PT (1) PT1328269E (de)
SI (1) SI1328269T2 (de)
SK (1) SK4032003A3 (de)
TR (1) TR200401264T4 (de)
WO (1) WO2002028346A2 (de)
YU (1) YU26103A (de)
ZA (1) ZA200303015B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
WO2003075917A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
JP2005528366A (ja) 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
EP1499306A4 (de) 2002-04-12 2007-03-28 Merck & Co Inc Bicyclische amide
ES2301833T3 (es) 2002-07-29 2008-07-01 Hoffmann La Roche Derivados de benzodioxol.
RU2339618C2 (ru) 2003-01-02 2008-11-27 Ф.Хоффманн-Ля Рош Аг Новые обратные агонисты рецептора св1
ATE400571T1 (de) 2003-01-02 2008-07-15 Hoffmann La Roche Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
UA83230C2 (ru) 2003-06-11 2008-06-25 Мерк Энд Ко., Инк. Замещенные производные 3-алкил- и 3-алкенилазетидинов
JP2007506654A (ja) 2003-06-20 2007-03-22 エフ．ホフマン−ラ　ロシュ　アーゲー Ｃｂ１受容体逆作動物質としての２−アミノベンゾチアゾール類
EP1498122A1 (de) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Halbfeste Systeme enthaltend Azetidin-Derivate
EP1498123A1 (de) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulgierende Systeme enthaltend Azetidin Derivate
EP1663215A1 (de) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Neue medizinische verwendung von selektiven cb1-rezeptorantagonisten
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
WO2005049615A1 (en) * 2003-11-21 2005-06-02 Pfizer Products Inc. Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
ES2298840T3 (es) 2003-12-08 2008-05-16 F. Hoffmann-La Roche Ag Derivados de tiazol.
DE602005023124D1 (de) 2004-01-28 2010-10-07 Hoffmann La Roche Spirobenzodioxole und deren verwendung als cb1-antagonisten
RU2380367C2 (ru) 2004-05-10 2010-01-27 Ф.Хоффманн-Ля Рош Аг Пиррол- или имидазоламиды для лечения ожирения
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
FR2876689B1 (fr) 2004-10-14 2008-02-22 Aventis Pharma Sa Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
CA2585175A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
RU2394027C2 (ru) 2004-10-27 2010-07-10 Ф. Хоффманн-Ля Рош Аг Новые индольные или бензимидазольные производные
JP4675969B2 (ja) 2004-11-09 2011-04-27 エフ．ホフマン−ラ ロシュ アーゲー ジベンゾスベロン誘導体
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
US20090264470A1 (en) * 2006-02-21 2009-10-22 Bennett Teresa A CB1 Antagonists and Inverse Agonists
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
AR061606A1 (es) * 2006-06-22 2008-09-10 Medichem Sa Formas solidas de rimonabant y procesos para su preparacion
EP2057144A4 (de) * 2006-09-01 2010-06-02 Hetero Drugs Ltd Neue polymorphe aus rimonabant
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
US7928123B2 (en) * 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP1953144A1 (de) * 2007-01-30 2008-08-06 Sandoz AG Polymorphe Formen von N-Piperidin-5-(4-chlorphenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolcarboxamid
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AU2008351943B2 (en) * 2007-12-18 2013-12-19 Sanofi-Aventis Azetidine derivatives, their preparation and their application in therapy
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
BRPI0902481B8 (pt) 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes composição farmacêutica compreendendo hemopressina e seu uso.
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61928B1 (en) † 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
JPH04360167A (ja) * 1991-06-06 1992-12-14 Mitsubishi Kasei Corp 近接帯電装置
FR2713225B1 (fr) † 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
JPH07209959A (ja) * 1994-01-24 1995-08-11 Ricoh Co Ltd 帯電装置
US5596106A (en) † 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
AU723879C (en) * 1996-10-31 2003-11-06 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
WO1999006110A1 (en) * 1997-07-29 1999-02-11 Silicon Genesis Corporation Cluster tool method and apparatus using plasma immersion ion implantation
EP0920864A1 (de) † 1997-12-03 1999-06-09 Pfizer Products Inc. Kombinationstherapie durch einen spezifischen beta-3 Agonisten und einen Appetithemmer
IL141769A0 (en) † 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation

Also Published As

Publication number Publication date
EP1328269B1 (de) 2004-05-26
WO2002028346A2 (fr) 2002-04-11
FR2814678B1 (fr) 2002-12-20
AU2001293936B2 (en) 2007-01-25
HUP0302044A3 (en) 2005-05-30
PT1328269E (pt) 2004-08-31
EA005924B1 (ru) 2005-08-25
DE60103556D1 (de) 2004-07-01
CA2424934A1 (fr) 2002-04-11
DK1328269T3 (da) 2004-09-20
AU9393601A (en) 2002-04-15
EP1328269B2 (de) 2008-07-30
EP1328269A2 (de) 2003-07-23
IL155236A0 (en) 2003-11-23
DK1328269T5 (da) 2009-03-16
HUP0302044A2 (hu) 2003-11-28
CN1473040A (zh) 2004-02-04
SI1328269T2 (sl) 2008-12-31
JP2004512279A (ja) 2004-04-22
BG107739A (bg) 2004-01-30
DE60103556T3 (de) 2009-04-09
MXPA03002845A (es) 2004-09-10
WO2002028346A3 (fr) 2002-08-29
ES2217191T3 (es) 2004-11-01
PL362833A1 (en) 2004-11-02
NZ524904A (en) 2004-11-26
TR200401264T4 (tr) 2004-07-21
EA200300441A1 (ru) 2003-08-28
KR20030036885A (ko) 2003-05-09
EE200300121A (et) 2005-04-15
FR2814678A1 (fr) 2002-04-05
NO20031521D0 (no) 2003-04-03
SI1328269T1 (en) 2004-10-31
NO20031521L (no) 2003-04-24
BR0114410A (pt) 2004-02-17
DE60103556T2 (de) 2005-06-30
ES2217191T5 (es) 2009-02-16
HRP20030249A2 (en) 2005-02-28
DK1328269T4 (da) 2008-11-24
ZA200303015B (en) 2004-02-26
SK4032003A3 (en) 2003-09-11
CN100409845C (zh) 2008-08-13
YU26103A (sh) 2006-08-17
JP4221221B2 (ja) 2009-02-12

Similar Documents

Publication Publication Date Title
ATE267595T1 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten
DE60022050D1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
ATE255894T1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
IS2564B (is) Heterófjölhringjaefnasambönd og notkun þeirra sem metabótrópísk mótlyf gegn glútamat viðtökum
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
DE60206164D1 (de) Trisubstituierte-n-((1s)-1,2,3,4-tetrahydro-1-naphthalenyl) benzamide welche p2x3 und p2x2/3 enthaltende rezeptoren inhibieren
DE60228317D1 (de) N-aryl-n'-arylcycloalkyl-harnstoff als mch antagonisten zur behandlung von fettleibigkeit
DE502004011551D1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen
DE69917230D1 (de) Kombinationspräparat, das selektive nmda nr2b-antagonisten und cox-2 inhibitoren enthält
ATE366572T1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
ATE320832T1 (de) Behandlung von haarfollikeln mit neurokinin 1 rezeptor antagonisten
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
DE69731657D1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
DE50210037D1 (de) VERWENDUNG VON WIRKSTOFFEN MIT õ-OPIOID-REZEPTOR AGONISTISCHER WIRKUNG UND OPIOID-REZEPTOR ANTAGONISTISCHER WIRKUNG ALS KOMBINATIONSARZNEIMITTEL ZUR KREBSBEHANDLUNG
ATE255452T1 (de) Antagonismus des estrogen-rezeptors-beta und knochenkrankheiten
DE69923982D1 (de) Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten
ATE492281T1 (de) Verwendung von glucocorticoid-rezeptor- spezifischen antagonisten zur behandlung von delirium
MXPA01009174A (es) Antagonistas de endotelina novedosos derivados de piridazina.
ATE396996T1 (de) Selektive d1/d5 rezeptorantagonisten zur behandlung von fettleibigkeit und von zns störungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1328269

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1328269

Country of ref document: EP

REN Ceased due to non-payment of the annual fee